Sign In
Buy ZNTL
$4.74
-0.180 (-3.66%)
At Close: Jul 31, 2026
NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Co
Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm
11:00am, Saturday, 17'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmac
Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm
11:00am, Friday, 16'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmac
NEW YORK CITY, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Co
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. (“Zen
Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm
11:00am, Thursday, 15'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmac
NEW YORK CITY, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Co
Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm
10:30pm, Wednesday, 14'th Aug 2024
The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NAS
NEW YORK CITY, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Co
Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
01:00am, Wednesday, 14'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmac
NEW YORK CITY, NY / ACCESSWIRE / August 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Co
Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
11:15pm, Monday, 12'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharm
Levi & Korsinsky Reminds Zentalis Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZNTL
10:15am, Monday, 12'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis") (NASDAQ:ZNTL) concerning possibl
NEW YORK CITY, NY / ACCESSWIRE / August 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Co
Zentalis Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Zentalis (ZNTL)
11:07am, Sunday, 11'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis") (NASDAQ:ZNTL) concerning possibl
